Icon Plc $ICLR Shares Purchased by Ninety One UK Ltd

Ninety One UK Ltd raised its holdings in Icon Plc (NASDAQ:ICLR) by 0.4% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 3,006,141 shares of the medical research company’s stock after purchasing an additional 12,489 shares during the quarter. Icon comprises approximately 1.2% of Ninety One UK Ltd’s portfolio, making the stock its 24th largest holding. Ninety One UK Ltd owned about 3.72% of Icon worth $526,075,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Private Trust Co. NA grew its holdings in shares of Icon by 200.0% during the third quarter. Private Trust Co. NA now owns 141 shares of the medical research company’s stock worth $25,000 after buying an additional 94 shares during the last quarter. Ameritas Advisory Services LLC acquired a new stake in Icon during the 2nd quarter worth approximately $48,000. LRI Investments LLC purchased a new position in shares of Icon in the 2nd quarter valued at approximately $49,000. Blue Trust Inc. increased its holdings in shares of Icon by 44.0% in the second quarter. Blue Trust Inc. now owns 393 shares of the medical research company’s stock valued at $57,000 after purchasing an additional 120 shares during the period. Finally, Caitong International Asset Management Co. Ltd lifted its holdings in shares of Icon by 40,800.0% during the second quarter. Caitong International Asset Management Co. Ltd now owns 409 shares of the medical research company’s stock worth $59,000 after purchasing an additional 408 shares during the period. 95.61% of the stock is owned by hedge funds and other institutional investors.

Icon Trading Down 0.4%

Shares of Icon stock opened at $182.22 on Thursday. The company has a 50-day moving average of $174.83 and a two-hundred day moving average of $170.65. Icon Plc has a 12-month low of $125.10 and a 12-month high of $228.29. The company has a current ratio of 1.06, a quick ratio of 1.06 and a debt-to-equity ratio of 0.31. The stock has a market cap of $14.72 billion, a PE ratio of 24.66, a price-to-earnings-growth ratio of 3.39 and a beta of 1.25.

Analyst Upgrades and Downgrades

ICLR has been the topic of several recent research reports. Barclays boosted their price objective on shares of Icon from $185.00 to $200.00 and gave the company an “equal weight” rating in a research note on Monday, December 15th. Rothschild Redb raised shares of Icon from a “hold” rating to a “strong-buy” rating in a report on Wednesday, September 3rd. BMO Capital Markets assumed coverage on shares of Icon in a research report on Thursday, November 13th. They issued a “market perform” rating and a $175.00 price objective for the company. Jefferies Financial Group lowered Icon from a “buy” rating to a “hold” rating and lowered their price objective for the company from $220.00 to $175.00 in a report on Tuesday, September 9th. Finally, Leerink Partners set a $220.00 target price on Icon in a research note on Thursday, October 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and eleven have assigned a Hold rating to the stock. According to MarketBeat.com, Icon currently has an average rating of “Moderate Buy” and a consensus target price of $205.31.

About Icon

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.